Seasonal Affective Disorder — what supplements can adjunct to light therapy
Seasonal Affective Disorder is a recurrent depressive pattern with onset in autumn or winter (fall-winter type) or — less commonly — late spring/summer (summer-pattern). The two best-evidenced interventions are bright light therapy (10,000 lux, 30 minutes within the first hour after waking) and cognitive behavioural therapy adapted for SAD (CBT-SAD). Both have RCT evidence comparable to SSRIs in this population. Supplements have a narrower adjunct role — addressing vitamin D deficiency (common in higher latitudes during winter), supporting omega-3 status, and using melatonin in carefully timed low doses for circadian phase advance.
The supplement adjuncts with reasonable role
Vitamin D3
Test 25-OH-D and supplement to 30–50 ng/mL; typical maintenance 1,000–2,000 IU/day; up to 4,000 IU/day if deficient
Winter vitamin D deficiency is very common in temperate and higher-latitude populations. Observational and small interventional data link low 25-OH-D to seasonal mood symptoms. Whether vitamin D supplementation directly improves SAD remains debated — a few small RCTs are positive, larger trials (VITAL-DEP) didn't show benefit in unselected populations. Correction of measured deficiency is reasonable for general health regardless.
Omega-3 (EPA/DHA, EPA-dominant)
1–2 g/day total EPA+DHA, EPA-dominant ratio for depression; with meals
Meta-analyses of omega-3 in depression show modest benefit, particularly for EPA-dominant formulations at ≥60% EPA. SAD-specific trials are sparse but the general depression evidence applies. Cardiovascular co-benefit makes this a reasonable adjunct even with modest mood effect.
Melatonin (low-dose, evening or afternoon depending on chronotype)
0.3–1 mg taken 6–8 hours before sleep onset, NOT at bedtime, under clinician guidance
The phase-shift hypothesis of SAD posits that fall-winter SAD reflects circadian phase delay relative to the sleep-wake schedule. Low-dose melatonin taken 6–8 hours before sleep onset (afternoon or early evening, NOT at bedtime) produces phase advance and has small-RCT evidence (Lewy 2006) of mood improvement in phase-delayed SAD. Wrong-timed melatonin can worsen symptoms; this is a precision intervention.
SAMe (S-Adenosylmethionine)
400 mg twice daily, enteric-coated; titrate up if needed; screen for bipolar history first
SAMe has meta-analytic evidence for mild-to-moderate depression at 800–1600 mg/day. No SAD-specific trials. Reasonable adjunct if SSRI/SNRI is not initiated and the depressive component is mild-moderate, but requires screening for bipolar (mania risk) and coordination with prescriber.
Saffron extract (Crocus sativus)
28–30 mg/day standardised extract; allow 6–8 weeks
Saffron extract has the better-evidenced "natural antidepressant" profile (multiple RCTs in mild-to-moderate depression, meta-analyses). Not SAD-specific but reasonable adjunct. See saffron vs 5-HTP comparison for the detailed evidence.
What to skip
- St John's wort with concurrent SSRI / SNRI / triptans — serotonin syndrome risk. Has its own RCT evidence in depression but interaction profile (CYP3A4 induction) makes it a more complex choice than saffron.
- 5-HTP with serotonergic medications — same serotonin syndrome concern, weaker evidence than saffron.
- "Mood boosters" with proprietary blends — without standardised actives at trial doses, you're paying for label promises.
- High-dose vitamin D (megadose >10,000 IU/day chronic) — hypercalcemia risk; the U-shaped curve for mood signal isn't established.
- Melatonin at bedtime "for SAD" — wrong-timed melatonin can worsen phase-delay symptoms; only afternoon/early-evening low-dose has phase-advance rationale.
- Untimed bright supplements / "natural light pills" — there's no oral substitute for light therapy.
The clinical framework that dominates outcomes
- Bright light therapy — 10,000 lux light box, 30 minutes within the first hour after waking, daily through the SAD season. The single most important intervention.
- CBT-SAD — adapted cognitive behavioural therapy targeting maladaptive thoughts and avoidance behaviours; trial evidence comparable to light therapy with possibly better off-season durability.
- SSRIs (fluoxetine, sertraline) or bupropion — first-line pharmacological options. Bupropion XL has FDA approval for SAD prevention (start ~late September, continue through winter).
- Consistent sleep timing — fixed wake time, morning light exposure, evening light dimming. Behavioural circadian alignment matters.
- Outdoor morning light exposure — even on overcast days, outdoor light substantially exceeds indoor light. 30 minutes outside in the morning is a free intervention.
- Aerobic exercise — independent antidepressant effect; outdoor morning aerobic exercise stacks light and exercise effects.
What to track
SIGH-SAD scale or PHQ-9 weekly during the SAD season. Sleep midpoint and wake time consistency. Light therapy adherence. 25-OH-D level (autumn baseline and winter midpoint). Reverse-pattern alert: if antidepressant treatment precipitates hypomania, restless activation, or sleep loss, reassess for bipolar spectrum and adjust treatment with clinical care.